JP2012523418A - 認知機能低下の阻害剤 - Google Patents

認知機能低下の阻害剤 Download PDF

Info

Publication number
JP2012523418A
JP2012523418A JP2012504788A JP2012504788A JP2012523418A JP 2012523418 A JP2012523418 A JP 2012523418A JP 2012504788 A JP2012504788 A JP 2012504788A JP 2012504788 A JP2012504788 A JP 2012504788A JP 2012523418 A JP2012523418 A JP 2012523418A
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523418A5 (OSRAM
Inventor
エム． リシュトン、ギルバート
カタラーノ、スーザン
Original Assignee
コグニション セラピューティクス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コグニション セラピューティクス インク． filed Critical コグニション セラピューティクス インク．
Publication of JP2012523418A publication Critical patent/JP2012523418A/ja
Publication of JP2012523418A5 publication Critical patent/JP2012523418A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012504788A 2009-04-09 2010-04-06 認知機能低下の阻害剤 Pending JP2012523418A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16798409P 2009-04-09 2009-04-09
US61/167,984 2009-04-09
US30866710P 2010-02-26 2010-02-26
US61/308,667 2010-02-26
US30909110P 2010-03-01 2010-03-01
US61/309,091 2010-03-01
PCT/US2010/030130 WO2010118055A1 (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline

Publications (2)

Publication Number Publication Date
JP2012523418A true JP2012523418A (ja) 2012-10-04
JP2012523418A5 JP2012523418A5 (OSRAM) 2013-05-23

Family

ID=42936539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504788A Pending JP2012523418A (ja) 2009-04-09 2010-04-06 認知機能低下の阻害剤

Country Status (12)

Country Link
US (3) US8765816B2 (OSRAM)
EP (1) EP2416795B1 (OSRAM)
JP (1) JP2012523418A (OSRAM)
CN (2) CN102458435A (OSRAM)
AU (2) AU2010234518A1 (OSRAM)
BR (1) BRPI1007624A2 (OSRAM)
DK (1) DK2416795T3 (OSRAM)
ES (1) ES2545795T3 (OSRAM)
IL (1) IL215645A0 (OSRAM)
RU (1) RU2595720C2 (OSRAM)
SG (2) SG10201404913QA (OSRAM)
WO (1) WO2010118055A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540737A (ja) * 2013-10-28 2016-12-28 ドレクセル ユニバーシティ 注意障害用および認知障害用ならびに神経変性障害に関連する認知症用の治療剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2416795T3 (en) 2009-04-09 2015-08-31 Cognition Therapeutics Inc INHIBITORS OF cognitive decline
SG10201506978UA (en) 2009-07-31 2015-10-29 Cognition Therapeutics Inc Inhibitors Of Cognitive Decline
EP2670402B1 (en) 2011-02-02 2017-09-20 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
US20170197977A9 (en) * 2011-08-25 2017-07-13 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
CA2846611A1 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
MX2014011315A (es) 2012-03-20 2014-10-17 Adamed Sp Zoo Derivados de sulfonamida de bencilamina para el tratamiento de enfermedades del sistema nervioso central.
JP6517827B2 (ja) * 2014-01-31 2019-05-22 コグニション セラピューティクス，インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
EP4153209A1 (en) 2020-05-20 2023-03-29 The Board of Trustees of the University of Illinois Method for treating lysosomal storage diseases with histatin peptides

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502216A (OSRAM) * 1981-01-28 1982-12-16
JPS62283922A (ja) * 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
JPH01180822A (ja) * 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
JPH03246258A (ja) * 1990-02-23 1991-11-01 Shionogi & Co Ltd ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
JPH09504032A (ja) * 1991-08-23 1997-04-22 エヌピーエス・ファルマシューティカルズ，インコーポレイテッド カルシウム受容体に活性なアリールアルキルアミン
JPH10513436A (ja) * 1994-10-21 1998-12-22 エヌピーエス・ファーマシューティカルズ・インコーポレイテッド カルシウム受容体活性化合物
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
WO2003016274A2 (en) * 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
JP2004002517A (ja) * 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
WO2008042755A2 (en) * 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
JP2008517047A (ja) * 2004-10-21 2008-05-22 メルク シャープ エンド ドーム リミテッド アルツハイマー病の治療用のピペリジン及び関連化合物
WO2009054468A1 (ja) * 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1093079A (zh) * 1993-03-30 1994-10-05 陈英俊 由具有愈创木酚结构之香辛类化合物及其去氢化合物衍生之肾上腺素激性乙型阻断剂
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
AU2005253776B8 (en) 2004-06-21 2012-02-02 King's College London Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
BRPI0608076A2 (pt) 2005-03-05 2009-11-10 Abbott Gmbh & Co Kg método de seleção, processo para purificação de oligÈmeros beta-a não difusìveis, anticorpos seletivos contra os ditos oligÈmeros beta-a não difusìveis e um processo para fabricação dos ditos anticorpos
EP1896005A4 (en) 2005-06-15 2009-11-11 Darrick S H L Kim SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
JP2009530305A (ja) 2006-03-17 2009-08-27 ハーバルサイエンス シンガポール ピーティーイー． リミテッド ウコン種を含む抽出物および方法
EP2007385A4 (en) 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
JP2010527375A (ja) 2007-05-15 2010-08-12 ヘリコン セラピューティクス，インコーポレイテッド Ｇｐｒ１２の阻害による認知障害の治療方法
WO2009059214A1 (en) 2007-11-02 2009-05-07 The Regents Of The University Of California Abeta-binding small molecules
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
DK2416795T3 (en) 2009-04-09 2015-08-31 Cognition Therapeutics Inc INHIBITORS OF cognitive decline
SG10201506978UA (en) 2009-07-31 2015-10-29 Cognition Therapeutics Inc Inhibitors Of Cognitive Decline
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
US20170197977A9 (en) 2011-08-25 2017-07-13 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502216A (OSRAM) * 1981-01-28 1982-12-16
JPS62283922A (ja) * 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
JPH01180822A (ja) * 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
JPH03246258A (ja) * 1990-02-23 1991-11-01 Shionogi & Co Ltd ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
JPH09504032A (ja) * 1991-08-23 1997-04-22 エヌピーエス・ファルマシューティカルズ，インコーポレイテッド カルシウム受容体に活性なアリールアルキルアミン
US6211244B1 (en) * 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
JPH10513436A (ja) * 1994-10-21 1998-12-22 エヌピーエス・ファーマシューティカルズ・インコーポレイテッド カルシウム受容体活性化合物
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
WO2003016274A2 (en) * 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
JP2004002517A (ja) * 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
JP2008517047A (ja) * 2004-10-21 2008-05-22 メルク シャープ エンド ドーム リミテッド アルツハイマー病の治療用のピペリジン及び関連化合物
WO2008042755A2 (en) * 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2009054468A1 (ja) * 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014016660; ＤＥＤＯＶ．，Ｖ．　Ｎ．，ＥＴ　ＡＬ．: '"Ｇｉｎｇｅｒｏｌｓ：　ａ　ｎｏｖｅｌ　ｃｌａｓｓ　ｏｆ　ｖａｎｉｌｌｏｉｄ　ｒｅｃｅｐｔｏｒ　（ＶＲ１）　ａｇｏｎｉｓｔｓ"' ＢＲＩＴＩＳＨ　ＪＯＵＲＮＡＬ　ＯＦ　ＰＨＡＲＭＡＣＯＬＯＧＹ ＶＯＬ．１３７, 2002, ＰＰ．７９３-７９８ *
JPN6014016662; ＧＲＺＡＮＮＡ，Ｒ．，ＥＴ　ＡＬ．: '"Ｇｉｎｇｅｒ-　Ａｎ　Ｈｅｒｂａｌ　Ｍｅｄｉｃｉｎａｌ　Ｐｒｏｄｕｃｔ　ｗｉｔｈ　Ｂｒｏａｄ　Ａｎｔｉ-Ｉｎｆｌａｍｍａｔｏｒｙ　Ａｃｔｉｏｎｓ"' ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＦＯＯＤ ＶＯＬ．８，ＮＯ．２, 2005, ＰＰ．１２５-１３２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540737A (ja) * 2013-10-28 2016-12-28 ドレクセル ユニバーシティ 注意障害用および認知障害用ならびに神経変性障害に関連する認知症用の治療剤
US11744810B2 (en) 2013-10-28 2023-09-05 Drexel University Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder

Also Published As

Publication number Publication date
US8765816B2 (en) 2014-07-01
CN102458435A (zh) 2012-05-16
US20120095105A1 (en) 2012-04-19
EP2416795B1 (en) 2015-06-03
RU2595720C2 (ru) 2016-08-27
EP2416795A1 (en) 2012-02-15
AU2010234518A1 (en) 2012-02-02
BRPI1007624A2 (pt) 2016-07-26
US9365491B2 (en) 2016-06-14
AU2015242954B2 (en) 2016-08-25
SG10201404913QA (en) 2014-11-27
US20160355458A1 (en) 2016-12-08
DK2416795T3 (en) 2015-08-31
WO2010118055A1 (en) 2010-10-14
RU2011145321A (ru) 2013-05-20
AU2015242954A1 (en) 2015-10-29
IL215645A0 (en) 2012-01-31
SG176772A1 (en) 2012-01-30
HK1167323A1 (en) 2013-01-04
ES2545795T3 (es) 2015-09-15
CN105968022A (zh) 2016-09-28
US20140371324A1 (en) 2014-12-18
EP2416795A4 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
JP2012523418A (ja) 認知機能低下の阻害剤
US9815770B2 (en) Inhibitors of cognitive decline
US9499462B2 (en) Isolated compounds from turmeric oil and methods of use
US20170049723A1 (en) Isolated compounds from turmeric oil and methods of use
HK1167323B (en) Inhibitors of cognitive decline
HK1171624B (en) Inhibitors of cognitive decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150127